全球癌症免疫疗法药物研发外包市场规模、份额、趋势及成长分析报告（2026-2034年）

癌症免疫疗法药物研发外包市场规模预计将从 2025 年的 23 亿美元成长到 2034 年的 56.2 亿美元，2026 年至 2034 年的复合年增长率为 10.42%。

由于对创新癌症治疗方法的需求不断增长，以及药物研发过程日益复杂，癌症免疫疗法药物研发外包市场预计将显着成长。免疫疗法是一种极具前景的治疗方法，它利用人体自身的免疫系统来靶向并摧毁癌细胞。随着製药公司寻求加快药物研发进程并降低成本，免疫疗法研发活动的外包变得越来越普遍，预计该市场将稳步扩张。

此外，免疫疗法技术的进步正在推动市场创新。单株抗体、CAR-T细胞疗法和免疫查核点抑制剂等新型疗法的研发正在革新癌症治疗，并为外包合作创造了新的机会。这些创新不仅提高了癌症治疗的疗效，也需要专业的洞察力和资源，因此外包对许多机构来说都极具吸引力。随着研发工作不断探索新的免疫疗法和联合治疗，在改善患者预后和加速药物研发进程的推动下，免疫肿瘤药物研发外包市场预计将进一步扩张。

此外，免疫肿瘤药物研发外包领域正在经历一场变革，合作与策略伙伴关係的重要性日益凸显。随着相关人员认识到利用外部专业知识和资源的价值，製药公司与受託研究机构（CRO）之间的联盟也变得越来越普遍。这些伙伴关係使企业能够获得专业知识、先进技术和高效流程，从而增强其药物研发管线。随着免疫肿瘤药物研发外包市场的不断发展，对合作与创新的重视将在推动未来成长方面发挥关键作用。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

第四章 全球癌症免疫疗法药物研发外包市场（依服务类型划分）

• 市场分析、洞察与预测
• 标靶分子鑑定与检验
• 先导筛检与表征
• 基于细胞的检测

第五章 全球癌症免疫疗法药物研发外包市场（依癌症类型划分）

• 市场分析、洞察与预测
• 肺
• 乳癌
• 冒号
• 黑色素瘤
• 摄护腺
• 头部和颈部
• 卵巢
• 胰臟

6. 全球癌症免疫疗法药物研发外包市场（依药物类型划分）

• 市场分析、洞察与预测
• 单株抗体
• 免疫调节剂
• 癌症疫苗和溶瘤病毒疗法
• 其他的

7. 全球癌症免疫疗法药物研发外包市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Covance Inc
  • Explicyte
  • Aquila BioMedical
  • Horizon Discovery Group PLC
  • Crown Bioscience Inc
  • Promega Corporation
  • HD Biosciences Co. Ltd
  • BPS Bioscience Inc
  • Genscript Biotech Corporation
  • DiscoverX Corporation
  • Celentyx Ltd
  • ImmunXperts SA
  • Personalis Inc
  • STC Biologics
  • Molecular Imaging Inc

The Cancer Immunotherapy Drug Discovery Outsourcing Market size is expected to reach USD 5.62 Billion in 2034 from USD 2.30 Billion (2025) growing at a CAGR of 10.42% during 2026-2034.

The cancer immunotherapy drug discovery outsourcing market is poised for significant growth, driven by the increasing demand for innovative cancer treatments and the rising complexity of drug development processes. Immunotherapy has emerged as a promising approach to cancer treatment, harnessing the body's immune system to target and destroy cancer cells. As pharmaceutical companies seek to accelerate their drug discovery efforts and reduce costs, the outsourcing of immunotherapy research and development activities is becoming increasingly common, positioning this market for robust expansion.

Moreover, advancements in immunotherapy technologies are driving innovation within the market. The development of novel therapeutic agents, such as monoclonal antibodies, CAR-T cell therapies, and immune checkpoint inhibitors, is revolutionizing cancer treatment and creating new opportunities for outsourcing partnerships. These innovations not only enhance the efficacy of cancer therapies but also require specialized expertise and resources, making outsourcing an attractive option for many organizations. As research continues to explore new immunotherapeutic approaches and combination therapies, the cancer immunotherapy drug discovery outsourcing market is likely to expand further, driven by the promise of improved patient outcomes and accelerated drug development timelines.

Additionally, the growing emphasis on collaboration and strategic partnerships is shaping the cancer immunotherapy drug discovery outsourcing landscape. As stakeholders recognize the value of leveraging external expertise and resources, the formation of alliances between pharmaceutical companies and contract research organizations (CROs) is becoming more prevalent. These partnerships enable companies to access specialized knowledge, advanced technologies, and efficient processes that can enhance the drug discovery pipeline. As the cancer immunotherapy drug discovery outsourcing market continues to evolve, the focus on collaboration and innovation will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service Type

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

By Cancer Type

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Head and Neck
• Ovarian
• Pancreatic

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• Others

COMPANIES PROFILED

• Covance Inc, Explicyte, Aquila BioMedical, Horizon Discovery Group PLC, Crown Bioscience Inc, Promega Corporation, HD Biosciences Co Ltd, BPS Bioscience Inc, Genscript Biotech Corporation, DiscoverX Corporation, Celentyx Ltd, ImmunXperts SA, Personalis Inc, STC Biologics, Molecular Imaging Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service Type
• 4.2. Target Identification and Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lead Screening and Characterization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell-based Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Prostate Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Head and Neck Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Ovarian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Pancreatic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Type
• 6.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Vaccines and Oncolytic Viral Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Service Type
  • 7.2.2 By Cancer Type
  • 7.2.3 By Drug Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Service Type
  • 7.3.2 By Cancer Type
  • 7.3.3 By Drug Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Service Type
  • 7.4.2 By Cancer Type
  • 7.4.3 By Drug Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Service Type
  • 7.5.2 By Cancer Type
  • 7.5.3 By Drug Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Service Type
  • 7.6.2 By Cancer Type
  • 7.6.3 By Drug Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Covance Inc
  • 9.2.2 Explicyte
  • 9.2.3 Aquila BioMedical
  • 9.2.4 Horizon Discovery Group PLC
  • 9.2.5 Crown Bioscience Inc
  • 9.2.6 Promega Corporation
  • 9.2.7 HD Biosciences Co. Ltd
  • 9.2.8 BPS Bioscience Inc
  • 9.2.9 Genscript Biotech Corporation
  • 9.2.10 DiscoverX Corporation
  • 9.2.11 Celentyx Ltd
  • 9.2.12 ImmunXperts SA
  • 9.2.13 Personalis Inc
  • 9.2.14 STC Biologics
  • 9.2.15 Molecular Imaging Inc